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A b s t r a c t  
The present study was designed to formulate matrix type transdermal patches of a potent anti 
atherosclerotic botanical Emblica officinalis on a mercury substrate and evaluated for 
physicochemical parameters like thickness, % flatness, weight variation, moisture uptake, moisture 
content, folding endurance, elongation and drug content values. Further, in vivo drug release was 
also observed by HPLC in rabbit serum. Four formulations were prepared using different ratio of 
matrix forming polymers, plasticizer and penetration enhancers. Formulations E-1, E-2, E-3 and E-4 
were composed of Ethyl cellulose (EC) and Hydroxypropyl Methylcellulose (HPMC) with the 
following ratios: 6:4, 7:3, 8:2 and 9:1. In vitro cumulative amounts of the permeated drug were 
observed 48.53, 55.46, 73.26 and 99.72% in 48 hrs from the four formulations. The release profile of 
the optimized formulation E-4; r2 = 0.984 (Higuchi) showed that permeation of the drug controlled by 
a diffusion mechanism. The cumulative amount of the permeated drug after 48hrs from E-4 was 
343.95mcg/cm2. Permeability coefficient was calculated 7.16mcg/cm2/hr. Based on physicochemical 
and in vitro skin permeation studies, E-4 was chosen for further in vivo studies. Blood plasma 
concentration of E-4 after 48 hrs was 0.2914mcg/cm2. Skin permeation performance and scanning 
electron microscopic studies revealed that formulation E-4 was found to be better than other 
formulations and it was selected as the optimized formulation. The skin irritation tests showed 
negligible erythema and edema. The developed transdermal patches may increase the efficacy of E. 
officinalis for the therapy of atherosclerosis.  
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Introduction  
Many advances have been made in recent years in the area of 
biopharmaceutical technology especially in the field of Transdermal 
Drug Delivery Systems (TDDS). The systemic delivery of drugs 
through TDDS is one area in which significant changes and 
improvements have been made to achieve an adequate treatment 
of chronic diseases [1,2]. In a broad sense, all topically 
administered polymeric drug formulations deliver the active 
ingredient into the general circulation [3,4]. Increasing prevalence 
of chronic diseases is also pushing strong demand for TDDS.  
WHO has also recommended the use of the herbal drugs which 
are safe and effective as compare to modern drugs. This leads to 
increasing demand for herbal products with anti-atherosclerotic 
activity [5]. Herbal transdermal formulation demonstrated 
significant anti-inflammatory activity against carrageenan-induced 
oedema in Wistar albino rats similar to standard formulation [6,7,8]. 
Currently synthetic drugs administered through transdermal 
patches form a major line of treatment in the management of 
chronic diseases like hypertension, atherosclerosis, diabetes etc. 
[9,10] but they may have several side effects. A targeted and safe 
drug delivery could improve the performance of some classical 
herbal medicines. Novel drug delivery technologies have increased 
the significance to attain modified delivery of herbal active 
bioingredients thereby, increasing the efficacy and therapeutic 
value as well as reducing toxicity. This is the fundamental idea 
behind integrating novel method of drug delivery in herbal 
medicines. Thus, it is important to integrate novel drug delivery 
system with medicinally important botanicals to fight against more 
serious diseases [11,12]. Emblica officinalis was selected on the 
basis of its synergistic action in suppressing hyperlipidemia. The 
plant E. officinalis commonly known as amla is highly valued in 
traditional Indian medicine [13]. It contains many active 
components i.e. ascorbic acid, tannins, trigalloylglucose, 
flavonoids, polyphenols (gallic acids, ellagic acid and phyllemblic 
acid), etc. which shows significant hypolipidemic activity [14,15].  
The supplementation of gallic acid (Figure.1) may have a potential 
hypolipidemic effect on mice fed high-fat diet. Here, an attempt was 
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made to analyze the in vitro and in vivo permeation herbal drug 
through extracorporeal device in to the systemic circulation. The 
presence of this predominantly phenolic analyte, i.e. gallic acid was 
confirmed by HPLC. Therefore, aim of this study was to formulate 
and optimize topically administered herbal patches subjected to in 
vitro and in vivo evaluation for drug penetration in male rabbits.   
 
 
Figure. 1- Gallic Acid 
 
Material and Methods   
Emblica officinalis dry extract (B.No.- 108035) was procured as the 
gift sample from Sanat Product Ltd., U.P., India; Hydroxy Propyl 
Methyl Cellulose was kindly supplied by Cadila Pharmaceuticals 
Limited, Ahmadabad, Gujarat, India; Ethyl Cellulose gifted by Asha 
Cellulose (I) Pvt. Ltd., Valsad, India. All other chemicals used were 
of analytical grade. MilliQ water was used throughout the study.  
Transdermal patch preparation 
The patches were formulated by incorporating dibutyl phthalate 
(10% w/w of dry polymer) as a plasticizer and PEG 400 (10% w/w 
of dry polymer) as a permeation enhancer. The polymeric casting 
solutions were prepared by dissolving EC and HPMC (ratios 6:4, 
7:3, 8:2 and 9:1 in formulations E-1, E-2, E-3 and E-4 respectively), 
plasticizer, penetration enhancer in 10 ml blend of chloroform and 
ethanol (90%) using a magnetic stirrer to get uniform solution. The 
dry extract of E. officinalis (5 mg/cm2) was added slowly to the 
solution and dissolved by continuous stirring for 30 min. This 
polymeric solution was poured on to the mercury surface (25 cm2) 
contained in the laboratory fabricated moulds with raised edges 
[16]. The moulds were kept on a horizontal surface. The rate of 
evaporation was controlled by inverting a funnel over the mould. 
After 24 h, the dried cast films were then detached from the 
mercury substrate and cut to generate transdermal patch of 1.0 
cm2 diameter (Figure. 2). The formulated patches were stored in 
dessicator until further evaluation. A thin layer of drug-compatible, 
hypoallergenic pressure sensitive adhesive polymer silicone 
adhesive applied on the external surface of transdermal patches to 
provide intimate contact of TDDS with the hair cleaned skin of 
rabbit [17].  
 
Figure.2: Transdermal patch of Emblica officinalis,  E-4 (1.0 cm2) 
formulated by EC and HPMC (9:1) 
Statistical analysis 
Statistical evaluation was carried out with SPSS 14.0 (SPSS Inc. 
Chicago, Illinois, USA). All values were expressed as mean + 
SEM. The kinetics of drug release from the patches was explained 
by zero-order, first-order, Higuchi's.  
Evaluation of patches 
Physical characterization  
The thickness of the dried films was measured at five different 
places using thickness gauze (Instrumentation, India) and their 
mean μ S.E.M. values (øm) were calculated [18]. The six dried 
patches of 1cm2 were cut and weighed on electronic balance to 
check the uniformity of weight and then mean μ S.E.M. (mg/cm2) 
was calculated [19]. Folding endurance of the film was determined 
by repeatedly folding a small strip of at the same place till it broke 
[20]. Flatness of patches was observed by cutting strips of patches 
from center, left and right position followed by measuring the length 
of each strip. The variation in length of strip omitted percent 
constriction, with 0% constriction equivalent to 100% flatness [21].  
Constriction (%) = (l1-l2)/l1ï100 
Where l1= initial length of each strip; l2= final length 
Uniformity of drug content of the patches estimated by taking three 
patches (1cm2) in separate stoppered conical flasks containing 25 
ml. of casting solvent, stirred vigorously for 4 hours on a magnetic 
stirrer. The above solutions were filtered (0.22 μ) and their drug 
content was estimated from the standard curves by using gallic 
acid reference standard (Sigma) at 273nm. Casting solvent of free 
film (non-medicated) was taken as blank. The patches for each 
drug were tested for their water absorption capacities. The 
prepared patches are weighed individually and placed in a 
desiccators containing activated silica at room temperature for 24 
h. Each patch was weighed repeatedly after a specified interval 
until they showed a constant weight. The percent moisture content 
is calculated using following formula [21,22].  
% Moisture content Initial weight ă Final weight  
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= Initial weight x100
 
A weighed patch kept in desiccators at room temperature for 24 
hours was taken out and exposed to 84% relative humidity 
(saturated solution of potassium chloride) in desiccators until a 
constant weight for the film was obtained. The % moisture uptake 
is calculated as given below [21]. 
% Moisture uptake =      
Final weight- Initial 
weight x100 
Initial weight 
 
The tensile strength of patches was determined by gradually 
increasing the pulling force till the patch broke. The percentage 
elongation was calculated as Kg/mm2 by fabricated tensile. 
Accelerated stability study of patches was performed for 3 months.  
In vitro skin permeation studies  
In vitro permeation study was carried out to evaluate active 
ingredient permeability through excised abdominal skin of rabbit 
using Modified  Franz diffusion cell consisting diffusional area of 
3.14 cm2 [23,24]. Hair on the abdominal area of Male New Zealand 
white rabbits weighing 1.2-1.8 kg were clipped off by applying 
depilatory for 10min and washed with distilled water one day before 
the experiment. The rabbits were anaesthetized with ether and the 
abdominal skin was excised followed by stitching and antiseptic 
cream was applied for healing. The epidermis of dissected skin 
was peeled from the dermis and rapidly rinsed with hexane and 
water to remove surface lipids. The skin was mounted immediately 
between the donor and receptor compartments of the diffusion cell 
with the epidermis facing upward to the donor compartment. The 
film to be tested was placed on the skin [25]. Isotonic phosphate 
buffer solution (pH 7.4) (22.5ml) was used as receptor phase and 
agitated with a magnetic stirrer at a speed of 600 rpm and the 
temperature was maintained at 37μ1ÀC. Samples (100øl) were 
withdrawn at regular intervals through the sampling port and fresh 
receptor fluid was added to maintain the constant volume of the 
receptor phase. The amount of drug permeated is quantified by 
using spectrophotometer [26]. The cumulative release was plotted 
against time and the permeation flux values were calculated from 
linear portion of the plot. The patches which had shown better 
permeation flux values were considered for in vivo studies on male 
albino rabbits [27].  
Kinetics of Release  
The intrinsic rate of drug release from TDDS is defined by Zero-
Order Model, First Order Model and Higuchi Model i.e. 
Zero-Order Model   
% Released = K
o t, Where Ko is the zero order release constant,  
First Order Model,  
Log (fraction unreleased) = (K1/2.303)t, Where K1  is the first-order 
release constant,  
Higuchi Model  
Mt  = Mo + KH x t1/2, Where Mt is the amount  of drug  released  at 
time  t  and K H is the Higuchi release rate [28].  
In vivo skin permeation studies 
The amount of permeated drugs in blood samples after 48 hrs of 
patch (E4) application on rabbit abdominal skin was quantified by 
HPLC. The blood samples were collected from marginal ear vein 
and kept for 1 hour at 37ĈC to allow it to clot followed by separation 
of serum by centrifugation at 4000 rpm for 20 minutes at 4ĈC. Drug 
separations were performed on a Waters RP HPLC using gradient 
elution equipped with w600 pump, Waters 2489 UV/VIS detector in 
combination with Empower2 software. Column used was C-18, (5 
øm column having 4.6X250 mm length and 4.6 mm internal 
diameter was used). Water-acetonitrile- acetic acid (88:10:2; v/v/v) 
was used as mobile phase delivered at a rate of 1 mL/min. 20øl of 
the sample solution was spiked with universal injector (Hamilton) 
on to the HPLC column. Effluent was monitored at 273 nm and 
compared with gallic acid reference standard (Sigma) [29,30].     
The patches applied for in vivo studies were also tested for their 
skin irritation potential. Patches were applied to the intact skin of 
rabbits occluded for 24 hrs and then removed for screening of 
irritancy, erythema or oedema [31,32]. 
Scanning Electron Microscopy (SEM) studies 
The shape and surface morphology of the drug dispersed patches 
before and after in vivo studies were investigated using scanning 
electron microscopy (JEOL JEM-100 CX II with ASID). This facility 
was kindly provided by Electron & Confocal Microscopy Lab, 
Cancer Pharmacology Division, IIIM, Jammu. Prior to mounting the 
patches onto the stubs, they were cut in to less than 3mm in length 
and stubs were than cleaned with polish (Pikal Metal Polish, Tokyo, 
PIKAL), followed by cleaning with diethyl ether, than double sticky 
cellophane tape was used to mount patches onto a stub. Silver 
paint was used to fix the sample on stubs. Stub was placed on a 
sample disc carrier (3-mm height, 10-mm diameter). Graphite 
coating was done by vacuum evaporator (vacuum 0.25 Torr) to 
enhance the better quality of picture and to improve secondary 
emission of samples. Interaction of the electron beam (40 kV) with 
the specimen produces a variety of physical phenomenon that 
detected, are used to form images and provide information about 
the specimens [33,34]. 
Results and Discussion  
The results of the physicochemical characterization i.e. thickness, 
% flatness, weight variation, moisture uptake, moisture content, 
folding endurance, elongation and drug content values of the the 
formulation are shown in Table 1.  
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Table 1: Physical Characterization of transdermal patches of Emblica officinalis 
 
Code EC:HPMC Thickness 
(øm) μ SD 
(n=3)   
% 
Flatness 
μ SD 
(n=3) 
Weight 
(mg/cm2) μ 
SD 
(n=3) 
Moisture
Uptake 
(%) μ SD
(n=3) 
Moisture 
content 
(%) μ SD
(n=3) 
Folding 
endurance 
(%)μ SD 
(n=3) 
Elongation 
at break (%) 
μ SD
(n=3) 
Drug 
content (%) 
μ SD
(n=3) 
E-1 6:4 195.27μ35 99.87 11.85μ0.02 6.54 μ 2.3 5.35 μ 2.9 134μ 1.8 0.708 μ0.13 98.3 μ 0.4
E-2 7:3 191.42μ14 99.97 12.05μ0.002 5.58 μ 2.7 4.38 μ 3.5 145μ 1.6 0.710 μ0.5 98.2 μ 0.3
E-3 8:2 189.13μ0.24 99.99 12.15μ0.02 4.94 μ 2.5 5.14 μ 2.3 148μ 1.4 0.881μ 0.24 99.0 μ 0.4
E-4 9:01 177.25μ0.23 100 12.34μ0.03 4.31μ0.74 3.14 μ 1.5 144μ 1.5 0.878 μ0.4 99.98μ 0.6
 
All the formulations found uniform in thickness ranging from 177.25 
to195.27 øm. The weights of prepared films ranged between 11.85 
mg and 12.34 mg, indicated that the films were uniform in weight. 
The flatness study revealed that E4 formulation had the same strip 
length before and after their cuts, further, E4 did not constrict with 
time indicating 100% flatness (Table1). The drug content of the 
prepared films ranged from 98.2% to 99.98% showed that the 
polymers, plasticizer and penetration enhancer used to prepare the 
films is capable of giving uniform drug content and minimal patch 
variability. Moisture uptake was observed more in patches having 
high content of HPMC (E1) with polymer ratio of EC: HPMC as 6: 4 
as compared to 9: 1 (E4) (Table 1). The results also conferred the 
work of Mosquera et al.  [35] Formulation E4 had shown minimum 
moisture content (3.14μ 1.5) as compared to other. Formulation E3 
and E4 had shown maximum folding endurance i.e. 148 and 144, 
indicated that these patches would not break and would maintain 
their integrity when applied on skin. 
The results of in vitro skin permeation studies of gallic acid from 
Emblica officinalis patches (E1,E2, E3 and E4) are shown in 
Figures 3. The % cumulative amount of drug released in 48 hrs 
from formulations (1 cm2) E1, E2, E3 and E4 was 48.53 and 55.46, 
73.26 and 99.72%) 
 
 
Figure. 3: In vitro drug permeation after 48 hrs from E1,E2, E3 and E4 formulations. Each point represents the mean μ SEM value (n=3) 
 
When the cumulative amount of drug permeated per square 
centimetre of E4 patches through rabbit skin was plotted against  
 
time, the permeation profiles of the drug followed mixed zero-
order/HiguchiÊs kinetics (Figure 4. a,b and c).  
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a.  
b.  
c.  
Figure. 4: (a,b,c) Graphical representation of drug release kinetics (Zero order, First order and HiguchiÊs order) 
 for transdermal formulation of E-4.  
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The in vitro release profiles of the formulations did not optimally fit 
into first-order kinetics (r2 = 0.808). However, the release profile of 
the formulated patches followed zero-order (r2= 0.967) and 
HiguchiÊs equation (r2 = 0.984), which indicates that the permeation 
of the drug from the E4 formulation was governed by a diffusion 
mechanism (Table.3). Graf of cumulative % drug released vs. 
square root of time was found linear also suggesting the Higuchian 
matrix diffusion from the E4 formulations (Figure. 4c). Maximum 
amount of drug released (99.72%) from formulation E4 was found 
whereas in case of E3 it was found 73.26% after 48 hrs of study 
(Table 3 and 2). 
 
Table 2: In vitro skin permeation of the E3 formulation 
Time(
hr) 
Concentration of 
withdrawal 
samples (mcg/ml) 
Cumulative 
amount 
released 
(mcg) 
Cumulative % 
Drug 
Released 
Cumulative %Drug remaining 
to Released 
0 0 0 0 100
2 13.856 311.76 6.2352 93.7648
4 27.316 614.61 12.2922 87.7078
6 40.8 918 18.36 81.64
18 85.2 1917 38.34 61.66
24 112.4 2529 50.58 49.42
36 156.8 3528 70.56 29.44
48 162.8 3663 73.26 26.74
(* Dissolution factor = 40) 
Table 3: In vitro skin permeation of the E4 formulation 
Time 
(hr) 
Concentration of 
withdrawl samples 
(mcg/ml) 
Cumulative 
amount 
released 
(mcg) 
Cumulative 
%Drug 
Released 
Cumulative % 
Drug 
remaining to 
Released 
0 0 0 0 100 
2 20.4 459 9.18 90.82 
4 51.6 1161 23.22 76.78 
6 59.6 1341 26.82 73.18 
18 112.4 2529 50.58 49.42 
24 144.4 3249 64.98 35.02 
36 194 4365 87.3 12.7 
48 221.6 4986 99.72 0.28 
(* Dissolution factor = 40) 
 
The diffusion studies revealed that 9:1 ratio of EC: HPMC (E4) 
maintain the rate of drug diffusion. Increased percentage of EC in 
E4 formulation may restrict the instant drug release, due to 
hydrophobic nature. It may also restrict the formation of gel layer 
around the patches. High percentage of HPMC polymer may cause 
rapid hydration and swelling of patches to form viscose gelatinous 
layer which may cause rapid drug release at the initial hours of 
patch application on skin (Figure. 3) but low amount of HPMC 
provide a consistent release of drug with out the loss of patch 
integrity [36]. Varying the ratio of polymer composition of 
formulation, the permeability coefficient and thickness of rate 
controlling membrane can alter the drug release rate. Formulation 
E-4 prepared with hydrophobic and hydrophilic copolymer 
containing dibutyl phthalate (10% w/w of dry polymer) as a 
plasticizer and PEG 400 (10% w/w of dry polymer) as a permeation 
enhancer showed best in vitro skin permeation through rabbit skin 
as compared with all other formulations. This may occur due to 
presence of both hydrophobic and hydrophilic polymer which 
allows little swelling but did not allow rapid diffusion of the drug 
from the patches.  
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Among all formulations, E4 patches considered for in vivo studies 
on male rabbits. The blood plasma concentration of the drug 
observed 0.291mcg/ml after 48 hrs (Figure. 5). Figure 4 also 
showed sustained release of the drug from formulation E4. HPLC 
analyses also indicated that gallic acid is present in the serum 
along with some more undetected compounds. During HPLC 
analysis 1 peak had shown almost same retention (tR = 4.39min) 
as shown by reference standard (tR = 4.42min) of gallic acid 
(Figure 6 and 7). 
Scanning electron microscopic studies revealed that patch (E4) 
had given smooth morphology with uniform distribution of drug 
particles before in vivo studies (Figure.8 ) but after in vivo study 
(48hrs) physical properties of E4 patch was unchanged and but it 
converted in to a porous membrane (Figure.9 ). 
 
 
 
Figure.5: Blood plasma concentration (mcg/cm2) profile of drug after trasdermal application of formulation E-4 (48hrs) on hair cleaned dorsal 
abdominal area of rabbit. 
 
Figure.6: HPLC chromatogram of gallic acid reference standard (Sigma) by Waters RP HPLC using gradient elution equipped with w600 pump. 
(tR = 4.42min, Run time = 20 min) 
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Figure.7: HPLC chromatogram (at 273 nm) of E. officinalis patch (E4) after 48 hrs in rabbit serum by Waters RP HPLC using gradient elution 
equipped with w600 pump. (tR = 4.39 min, Run time = 20 min). 
 
 
Figure. 8: Scanning electron photomicrograph of the transdermal patch of Embilica officinalis (E4), EC: HPMC (9:1) before in vitro application 
showed film was smooth, discrete, uniform distribution of drug and polymer   
 
 
Figure.9: SEM of E4, after 24 hrs in vivo permeation studies did not show change in the morphology of film. It indicated that the ratio of EC: 
HPMC as 9:1 for developing patches will maintain its physical properties even application on skin. Large no of holes also observed after permeation study 
indicated that sufficient amount of drug have been released during patch application on skin. 
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 Formation of small pores after in vivo application  indicated that 
there may be some release take placed during in vivo study and 
permeation study determined that what actual amount of 
substances (drugs) had permeated via skin. Skin irritation test were 
performed after in vivo studies to check any irrational effect of 
patches on rabbits. It was observed that E4 patch was free from 
skin irritant effect and there was no any sign of erythema after 48 
hrs. application on abdomen of rabbit. 
Conclusions 
Our study revealed that rate controlling membrane of Emblica 
officinalis (E4) have great utility and may be a viable option for 
effective and controlled release of drug in to the systemic 
circulation to manage atherosclerosis. The study confer that 
transdermal patches of Emblica are a promising prolonged delivery 
system for gallic acid with other substances and have reasonably 
good stability characteristics. In conclusion, on correlating all the 
formulations studied, E4 was found to be an efficient penetrative 
extracorporeal device. Incorporation of herbal drugs in novel drug 
delivery system may lead to an excellent result. Present study may 
also open up an attempt to utilize herbal drugs through TDDS.   
Transdermal patch of Emblica penetrates gallic acid successfully 
and it may be beneficial for topical use to reduce hyperlipidemia 
after  successive  preclinical  and  clinical  trial  to  bring  them  in  
market  via  a  suitable  drug delivery  system  for mankind. 
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